COMPARISON OF SWITCHING TO REDUCED DOSE VS CONTINUATION OF STANDARD DOSE ETANERCEPT FOR RHEUMATOID ARTHRITIS PATIENTS IN THE CORRONA REGISTRY

被引：2
|
作者：
Greenberg, J. D. [1 ,2 ]
Shan, Y. [2 ]
Reed, G. W. [2 ,3 ]
Bitman, B. [4 ]
Collier, D. [5 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] CORRONA Inc, Southborough, MA USA
[3] Univ Massachusetts, Sch Med, Worcestesr, MA USA
[4] Amgen Inc, San Francisco, CA USA
[5] Amgen Inc, Thousand Oaks, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1836
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0174
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [31] IMPACT OF BIOLOGIC DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATION FROM THE CORRONA REGISTRY
    Pappas, D. A.
    Reed, G. W.
    Bao, Y.
    Grant, S.
    Garg, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 226 - 226
  • [32] A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
    Greenberg, Jeffrey D.
    Reed, George
    Decktor, Dennis
    Harrold, Leslie
    Furst, Daniel
    Gibofsky, Allan
    DeHoratius, Ralph
    Kishimoto, Mitsumasa
    Kremer, Joel M.
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (07) : 1134 - 1142
  • [33] EFFECTIVENESS OF LOW AND HIGH DOSE METHOTREXATE IN COMBINATION WITH ADALIMUMAB IN A REAL WORLD SETTING: RESULTS FROM THE CORRONA RHEUMATOID ARTHRITIS REGISTRY
    Pappas, D.
    Griffith, J.
    Schlacher, C. A.
    Shan, Y.
    Karki, C.
    Kremer, J. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 827 - 827
  • [34] Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab.
    Di Poi, Emma
    Perin, Antonella
    Morassi, Maria Pia
    Del Frate, Marino
    Ferraccioli, Gianfranco
    De Vita, Salvatore
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (01) : 85 - 87
  • [35] The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
    Hansen, KE
    Hildebrand, JP
    Genovese, MC
    Cush, JJ
    Patel, S
    Cooley, DA
    Cohen, SB
    Gangnon, RE
    Schiff, MH
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (06) : 1098 - 1102
  • [36] Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis
    Takei, S
    Groh, D
    Bernstein, B
    Shaham, B
    Gallagher, K
    Reiff, A
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (07) : 1677 - 1680
  • [37] Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation
    Hsu, Li-feng
    Huang, Jin-ding
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (09) : 776 - 786
  • [38] INFLUENCE OF CONCOMITANT METHOTREXATE AND PREDNISOLONE DOSE ON DRUG INEFFICACY OF ETANERCEPT AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Ebina, K.
    Shi, K.
    Tomita, T.
    Kunugiza, Y.
    Hishitani, Y.
    Hirano, T.
    Ogata, A.
    Yoshikawa, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 237 - 237
  • [39] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
    Bathon, JM
    Martin, RW
    Fleischmann, RM
    Tesser, JR
    Schiff, MH
    Keystone, EC
    Genovese, MC
    Wasko, MC
    Moreland, LW
    Weaver, AL
    Markenson, J
    Finck, BK
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22): : 1586 - 1593
  • [40] Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
    Pappas, Dimitrios A.
    Kremer, Joel M.
    Griffith, Jenny
    Reed, George
    Salim, Bob
    Karki, Chitra
    Garg, Vishvas
    RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 375 - 389
12345